Difference between revisions of "Protein C, human (Ceprotin)"
Jump to navigation
Jump to search
(Created page with "Human protein C ==History of changes in EMA indication== *7/16/2001: Initial authorization as Ceprotin ==Also known as== *'''Brand name:''' Ceprotin Category:Fractionated...") |
m |
||
| Line 3: | Line 3: | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
*7/16/2001: Initial authorization as Ceprotin | *7/16/2001: Initial authorization as Ceprotin | ||
| + | *CEPROTIN is indicated for prophylaxis and treatment of purpura fulminans, coumarin-induced skin necrosis, and venous thrombotic events in patients with severe congenital protein C deficiency. | ||
==Also known as== | ==Also known as== | ||
Revision as of 00:57, 4 February 2023
Human protein C
History of changes in EMA indication
- 7/16/2001: Initial authorization as Ceprotin
- CEPROTIN is indicated for prophylaxis and treatment of purpura fulminans, coumarin-induced skin necrosis, and venous thrombotic events in patients with severe congenital protein C deficiency.
Also known as
- Brand name: Ceprotin